Dose Neurogenesis No.3 Microdose Psilocybin Capsules is a premium formula specifically developed to optimize both your neurological and mitochondrial functions. This convenient yet powerful micro-dose formula in 500mg capsule form aims to integrate seamlessly with those wanting to preserve their overall brain health by optimizing crucial bio-pathways relating to your overall mental performance. We have incorporated enhanced bioavailable ingredients that can cross the blood-brain barrier effectively to provide long-term benefits balanced with your on-demand needs.
Recommended use: Promotes mental clarity, memory, focus, mood balance, self-efficacy, energy, and brain health.
- Hot water extracted Lion’s Mane maximizes enzyme intake and digestion of chitin (mushroom cell wall) vs. raw Lion’s Mane powder
- Optimal extraction of mushroom Polysaccharides > 30% @ 7:1 Ratio Concentrate
- Harvested only from the fruiting bodies of the psilocybin and medicinal mushroom. No added fillers such as starch, grains or mycelium
- Non-GMO, Vegan Friendly + Gluten Free
- 500mg capsule
- 25 capsules per bottle
Each bottle contains 25 capsules. Each capsule is 500mg (150mg of Psilocybe Cubensis (Golden Teacher), 300mg of Certified Organic Lion’s Mane Extract 7:1 Ratio, and 50mg of L-Carnitine). Dose Neurogenesis No.3 Microdose Psilocybin Capsules
The benefits of full-dose psychedelics
While more than a thousand early studies linked psychedelic use with beneficial effects , there was a 40-year pause on psychedelic research following the prohibition of these substances . Despite continued prohibition, modern research has revealed the promising potential of LSD and psilocybin for treating alcohol and tobacco dependence [14,15,16,17], depression [18, 19], and end-of-life anxiety [20,21,22], while related research on 3,4-methylenedioxymethamphetamine (MDMA) has shown great promise for treating post-traumatic stress disorder . Psychedelics can also increase openness and occasion mystical-type experiences in healthy controls [24,25,26]. As full-dose psychedelics appear to aide in the relief of severe, chronic psychiatric conditions (e.g. depression, anxiety, PTSD), milder mental health concerns may plausibly be treated by lower, recurring doses. This is especially worth considering if certain full-dose outcomes are found to rely on purely pharmacologic mechanisms rather than primarily on phenomenological experiences .
Limiting microdosing research to topics that have been investigated in full-dose research could prematurely overlook unpredicted and potentially distinct microdosing outcomes. Full-dose research has employed various focal assessments of symptomatology, mood, and personality that are likely applicable to microdosing research, but due to the low doses and lack of perceptual alteration intended in microdosing, other full-dose phenomena, such as ego dissolution and mystical-type experiences, are less relevant to microdosing research. Instead, as a means of preparing for a broad range of outcomes, the present work solicited open-ended reports of benefits and challenges. Additionally, as psychedelic substances act on distinct yet overlapping neural receptor sites, it seems plausible that distinct patterns could emerge for different substances. The present study thus included microdosers who used LSD, psilocybin, or both.
Free Expedited Shipping on orders over $250
We ship worldwide with tracking number
Discreet and vacuum sealed packaging for your privacy